Hyperkalemia

Congestive Heart Failure (CHF)

Chronic Kidney Disease (CKD)

End Stage Renal Disease (ESRD)

Renin-Angiotensin-Aldosterone (RAAS)

RLY5016 is a high capacity cation binder for the management of hyperkalemia in congestive heart failure (CHF) and chronic kidney disease (CKD) patients. This compound is currently in Phase 2 clinical testing.

Use of renin-angiotensin-aldosterone system (RAAS) blockade (ACE inhibitors, ARBs, aldosterone antagonists) has been shown to reduce mortality in CHF and CKD patients. However, potassium retention, leading to increased serum potassium, is a significant challenge to the broader use of RAAS blockade treatment.

Hyperkalemia is a serious medical condition that may lead to arrhythmia and sudden cardiac death. Currently, only acute treatments in the emergency room setting are available and significantly limited by side effects. Chronic heart failure and chronic kidney disease patients are the most likely populations to develop hyperkalemia due to impaired kidney function.